



**l'Assurance  
Maladie**

Agir ensemble, protéger chacun

# BIOSIMILAR INCENTIVES POLICY IN FRANCE

Stakeholder event on biosimilar medicinal products – 13/12/2022

# BIOSIMILARS IN FRANCE – KEY FIGURES

## Fast growing turnover


- 1,16 bn€ in 2021 (x 5,6 over 5 years)
- 54% hospital / 46% community pharmacies
- 48% of biologics market  
*(references with biosimilars)*
- 3% of total pharmaceutical market

*Gers data*



# BIOSIMILARS IN FRANCE – KEY FIGURES

Heterogeneous penetration rate (volume share, community)



Cnam data

# BIOSIMILARS : MAIN INCENTIVES

## Prescribers /hospital

- **Payment for performance** (2018-2022) → scope : epoetin, anti-TNF alpha (etanercept, adalimumab), insulin glargine, G-CSF (filgrastim, pegfilgrastim)
- **Gain sharing 20%** (2018) → scope : etanercept, insulin glargine, adalimumab
- **Gain sharing 30%** (« art. 51 » experimentation 2018-2022) in some hospitals (only project holders) → scope : etanercept, insulin glargin, adalimumab  
*assessment ongoing, may be extended nationwide*

## Prescribers/ community-based practitioners

- **Payment for performance** (2016) → scope : insulin glargin
- **Gain sharing 30% in 2022, 20% in 2023** (« amendment 9 ») → scope : etanercept, adalimumab, follitropin alpha, enoxaparin, insulin asparte

## Pharmacists

- **Substitution** (2022) of prescribed biological product with its biosimilar  
→ scope : filgrastim, pegfilgrastim (already high penetration rate)  
under certain conditions (no formal objection by the prescriber, patient and prescribed to be informed)  
*incentives not yet fully implemented*

# CHALLENGES 1/2 : INCREASE BIOSIMILAR UPTAKE

Initiation treatments with biosimilars tend to increase...

- **Cnam study on rheumatoid arthritis : share of patients with biosimilar (adalimumab or etanercept)**  
80% of new patients (between July 2020 and June 2021) vs 29% between July 2017 and June 2018

...but heterogeneous practices between hospital prescribers and non hospital prescribers

- **Ex : rheumatoid arthritis : share of patients with biosimilar (adalimumab)**  
86% during hospitalisation  
41% when prescribed by hospital (out-patient use)  
30% when prescribed by community-based practitioners

# CHALLENGES 2/2 : INCREASE INFORMATION TOWARDS PRESCRIBERS AND PATIENTS

Towards prescribers (community based): visits from health insurance delegates and physicians (2022-23)

- targeting general practitioners, rheumatologists, gastroenterologists, gynecologists, endocrinologists
- to promote use of biosimilars (initiation and switch)
- to inform about gain-sharing incentives

Towards patients

- in collaboration with patients associations
- leaflets to be handed by their physicians

**QU'EST-CE QU'UN MÉDICAMENT BIOSIMILAIRE ?**

Parmi les médicaments biologiques que votre médecin peut vous prescrire, certains ont des équivalents appelés « biosimilaires ». Ils existent depuis près de 20 ans. Ce sont des médicaments biologiquement comparables au médicament de référence.

**MÉDICAMENTS BIOSIMILAIRES AIDE À LA PRESCRIPTION** ADALIMUMAB Situation au 15 octobre 2022

Les médicaments biosimilaires disponibles de l'adalimumab se présentent sous les mêmes dosages et selon la même voie d'administration (usage sous cutané) que le médicament bioréférent.

Biosimilaires	Dosage / forme galénique	Conditionnement	Prix TTC (Mc de 1 ou 2)
HUMIRA®	20 mg solution injectable SÉRINGUE	Boîte de 2	280,71 €
AMGEVITA®	20 mg solution injectable SÉRINGUE	Boîte de 1	131,08 €

Biosimilaires	Dosage / forme galénique	Conditionnement	Prix TTC (Mc de 1 ou 2)
AMGEVITA®	40 mg solution injectable SÉRINGUE	Boîte de 1, 2 et 6	469,03 €
HUKYONORA®			
HULIO®			
HYRMOZ®			
IDACIO®			
INRALDI®			
YUFELMAB®	Boîte de 1, 2, 4 et 6		

**MÉDICAMENTS BIOSIMILAIRES**  
Pourquoi faut-il prendre le temps d'en parler ?

**l'Assurance Maladie**  
Agir ensemble, protéger chacun